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Valproic acid (VPA, 2-propylpentanoic acid) is an estab-
lished drug in the long-term therapy of epilepsy. Recently,
VPA was demonstrated to inhibit histone deacetylases
(HDACs) class I enzyme at therapeutically relevant con-
centrations, thereby, mimicking the prototypical histone
deacetylase inhibitors, tricostatin A (TSA) or suberoy-
lanilide hydroxamic acid (SAHA). In the present study, we
investigated the cellular effects of VPA, TSA and SAHA
on four human melanoma cell lines (WM115, WM266,
A375, SK-Mel28) with particular reference to the modu-
lation of regulators of apoptosis, including Bcl-2, BclXL,
Mcl-1, Apaf-1, BclXs, NOXA, TRAIL-R1, TRAIL-R2, cas-
pase 8, and survivin). Firstly, we found that VPA induced
apoptosis in two of the four human melanoma cell lines,
while both TSA and SAHA exhibited an antiproliferative
and apoptotic effects in all four cell lines, a different
expression of Bcl-2 and BclXL/S occurred. On the other
hand, SAHA and VPA modulated differently pro- and anti-
apoptotic factors. In particular, the treatment with VPA
enhanced the level of expression of survivin only in VPA-
resistant cell lines, whereas down-regulation of survivin
was induced by VPA and SAHA in VPA-sensitive cells.
In the latter, since activation of caspase 8 was docu-
mented, a receptor-mediated apoptosis was suggested.
Taken together, our results suggest that HDAC inhibitors
may represent a promising therapeutic strategy to treat
melanoma.
Keywords: BclX/Bcl2; melanoma; SAHA; survivin; TRAIL; val-
proic acid.
Introduction
The structure of chromatin may be altered by post-
translational modifications such as acetylation which play
a role in regulating gene expression. Two groups of en-
zymes, histone deacetylase (HDACs) and histone acetyl-
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transferases (HATs), determine the acetylation status of
histones. HDACs catalyse the removal of acetyl groups
from lysine residues in the amino-terminal tails of the
nucleosomal core histones.1,2 There are three classes of
HDACs, class I (HDACs 1, 2, 3 and 8), class II (HDACs
4, 5, 6, 7, 9 and 10) and class III. The latter is structurally
distant with respect to the others and is not inhibited by
HDAC inhibitors for classes I/II, often characterized by a
hydroxamic acid moiety.3,4 Alterations in the acetylation
levels of chromatin and deregulated function of HDACs
have been involved in tumorigenesis.5 Several HDAC in-
hibitors are currently in clinical trials as anticancer agents
since they show an inhibitory activity against cancer at
well-tolerated doses.6
Valproic acid (VPA, 2-propylpentanoic acid) is an es-
tablished drug in the long-term therapy of epilepsy. Al-
though VPA is well tolerated by patients, it can induce
birth defects such as neural tube closure and other malfor-
mations, if administered during early pregnancy.7,8 The
mechanism responsible for such defects is at yet unclear.9
Recently, VPA was demonstrated to inhibit corepressor-
associated HDACs, acting on class I more efficiently than
class II enzymes at therapeutically relevant concentrations
mimicking the prototypical histone deacetylase inhibitor,
tricostatine.10,11 Furthermore, VPA acts as a potent in-
ducer of differentiation in several types of transformed
cells.10 VPA shows mild adverse effects in adults even if
serum levels exceed the normal therapeutic range during
antiepileptic therapy.10 In addition, the daily doses of VPA
required to achieve therapeutic serum levels in patients
(20–30 mg/Kg) are moderate in comparison with those
required for other available inhibitors such as butyrate or
suberoylanilide hydroxamic acid (SAHA).2,12 Since VPA
is a well-tolerate drug even during long-term treatment,
it has been recently proposed as a useful drug in cancer
therapy.10 The mild side effects, mostly on the central ner-
vous system, may be reduced with appropriate modifica-
tion of the VPA molecule as demonstrated by S-4-yn-VPA
or derivates with longer side chains.13 In particular, such
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a drug appears promising as low toxicity agent given over
long time periods for chemoprevention and/or for control
of residual minimal disease.14
The main goal of the present study was to investigate
the effects of the treatment with VPA or other HDAC in-
hibitors (SAHA and TSA) on several human melanoma
cell lines (WM115, WM266, A375, SK-Mel28). We
observed in several—but not all—cases the induction
of apoptosis by the treatment with HDAC inhibitors.
Thereby, herein, we investigated the expression of anti-
or pro-apoptocic factors following treatment (exemplified
by Bcl-2, BclXL, Mcl-1, Apaf-1, BclXs, NOXA, Mcl-1
and survivin). In this context, since tumor necrosis fac-
tor (TNF) related apoptosis inducing ligand (TRAIL),
a member of the TNF family, can induce apoptosis in
melanoma cells depending on the levels of surface expres-
sion of the death receptors, particularly TRAIL-R2,15 the
possible involvement of TRAIL-R1 and -R2 in the ob-
served apoptosis was also investigated.
Our findings show for the first time that distinct hu-
man melanoma cell lines present a different balance in
the expression of pro- and anti-apoptotic factors either
at the basal level and following exposure to HDAC in-
hibitors. Interestingly, HDAC inhibitors modulate sur-
vivin expression in a different ways in distinct cell lines.
Materials and methods
Cell lines, treatments and reagents
Human WM115, SK-Mel28, WM266 and A375 cells
were purchased from ATCC and maintained under the
following conditions: WM266, SK-Mel28 and A375
in DMEM medium; WM266 in MEM and WM115
in BME medium. Cells cultured in DMEM or MEM
medium were supplemented with 10% fetal calf serum,
2% MEM vitamin, 1% non essential aminoacids, 1% an-
tibiotics/antimicotics (100 U/ml pennicillin, 100 µg/ml
streptomycin, 0.25 µg/ml amphotericine) while cells cul-
tured in BME medium were supplemented with 10%
fetal calf serum, 2% BME vitamin, 1% non essential
aminoacids, 1% antibiotics/antimicotics (100 U/ml pen-
nicillin, 100 µg/ml streptomycin, 0.25 µg/ml ampho-
tericine). All the cells were grown at 37◦C and 5% CO2.
A fixed number of cells (as reported in the legend of
figurers) were plated on 96-well plates and 24 h after
plating cells were treated with 1 mM VPA for 1 week or
with 100 ng/ml tricostatine (TSA) or with SAHA (4 µM)
for 72 h. At the end of the treatments the proliferative rate
of the cells were measured by the MTT (thiazolyl blue)
assay.
As positive control, exponentially growing Jurkat cells
were treated with anti-Fas antibody (1 µg/ml; mAB clone
APO 1–3 Kamya Biomedical Co.) for 24 h to activate cas-
pase 8 and therefore Fas-mediated apoptosis (90% apop-
tosis, data not shown). At the end of the treatment the
cells were processed for Western blot analysis.
Cell cycle analysis
To assess the percentage of cells in different cell cycle
phases, including cells with a subG1 DNA content (apop-
totic cells), cell cycle analysis was carried out. Subconflu-
ent cells were fixed in iced ethanol and kept at 4◦C until
staining for the cytofluorimetric analysis. The fixed cells
were washed once with 1ml phosphate-buffered saline
(PBS) containing 1% BSA and then incubated with PBS
containing 6.25 µg/ml RNAse (Sigma. St Louis, MO)
and 50 µg/ml of propidium iodide (PI) overnight at 4◦C
to stain DNA. Cells were acquired with a FACSscanplus
(Becton-Dickinson) equipped with an argon-ion laser (ex-
citation wavelength 488 nm, laser power 200 mW). The
sample flow rate during analysis did not exceed 500–600
cells/s. Typically 30000 cells were analysed per sample.
DNA deconvolutions were carried out using the software
program CELLQUEST (Becton-Dickinson). The experi-
ments were repeated at least four times.
Western blot analysis
Whole cells lysates were prepared suspending the cell
pellets in lysis buffer containing 20 mM TRIS-HCl,
pH7.5, 12 mM EDTA, 0.5 mM EGTA, 5 µM leu-
peptin, 0.15 µM pepstatin A, 0.5 mM PMSF and 1%
Triton-X100, homogenized at 4◦C. The protein content
was evaluated using Lowry method.16 The cells lysates
were mixed with 2X sodium dodecyl sulphate (SDS)-
containing buffer and loaded in polyacrylamide gels (SDS-
PAGE) according to literature method,17 and transferred
to PVDF sheet overnight.18 The sheets were incubated
overnight with anti-Bcl2 (1:100 Dako) or anti-BclXL/S
(1:2000, Pharmingen) or anti-Apaf-1 (1:1000, Sigma)
or anti-human caspase 8 (1:2000, Kamya Biomedical
Co) at 4◦C. The signal was developed with ECL-Plus
(Amersham-Biotech) according to the manufacturers in-
structions. Equal loading of protein on the gel was verified
by 10% SDS-PAGE and stained with Coomassie Brilliant
Blue R250. Furthermore, to check the correct loading
of the samples, the sheet was incubated with anti-β actin
antibody (1:1000; Sigma). The molecular weights were es-
timated using prestained markers. The results were anal-
ysed by densitometric analysis using ImageMaster soft-
ware (Pharmacia Biotech).
Determination of Histone H3
and H4 acetylation status
Accumulation of hyperacetylated histones H3 and H4
was analysed in cell lysates by western blotting using
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antibodies directed against acetylated histones H3 and
H4 (1:1000, UpState) or only against non acetylated hys-
tone H4 (1:1000, UpState). Whole-cell lysates were pre-
pared in denaturating SDS sample buffer and separated
on 15% SDS-polyacrylamide gels. Equal loading was
confirmed incubating the sheet with anti-non acetylated
H4.
RT-PCR
Total RNA was prepared from subconfluent cells using
the RNeasy Mini Kit from Qiagen. One microgram
of total RNA was reverse-transcribed and amplified
by means of an “Enhanced avian hs RT-PCR” (Sigma)
according to the manufacturer’s instructions. PCR was
performed at 93◦C for 5 min (first denaturation) and
then 35 cycles were run at 93◦C for 1 min (denaturation),
52◦C for 1.30 min (annealing) and 72◦C for 1 min
(extension) for TRAIL-R1 and R2; 95◦C for 10 min
(first denaturation); 40 cycles were run at 95◦C for 30 sec
(denaturation), 55◦C for 15 sec (annealing) and 72◦C
for 30 sec (extension) for survivin and NOXA; 40 cycles
were run for Mcl-1 at 95◦C (first denaturation) 30 sec,
61◦C (annealing) 15 sec and 72◦C 30 sec (extension).
The final extension was 10 min at 72◦C. PCR products
were analysed by agarose gel (1.5%) electrophore-
sis and photographed under UV light. Nucleotide
sequences of PCR primers were: TRAIL-R1-sense-
5′CGATGTGGTCAGAGCTGGTACAGC-3′ and anti-
nsense-5′-GGACACGGCAGAGCCTGTGCCAT C-3′ ,
217 bp amplified fragment; TRAIL-R2-sense-
5′-GGGAGCCGCTCATGAGGAAGTTGG-3′ and an-
tisense-5′GGCAAGTCTCTCTCCCAGCGT CTC-3′ ,
182 bp amplified product;19 survivin-sense 5′AAG-
AACTGGCCCTTCTTGGA-3′ and antisense-5′CAA-
CCGGACGAATGCTTTTT-3′ , 147 bp amplified frag-
ment;20 NOXA- sense- 5′GTCCGAGGTGCTCCA-
GTT-3′ and antisense-5′AAACGTGCACTCCCTG-
AGA-3′ (external primers) and sense-5′-GGGCTCTG-
TCGCTGAG-3′ and antisense-5′-TCGACCTCCTGAG-
AAAACT-3′ (internal primers) 226 bp amplified
fragment;21 Mcl-1-sense-5′CACGAGACGGTCTTCC-
AAGGCATGCT-3′ and antisense-5′-CTAGGTTGC-
TAGGGTGCAACTCT AGGA-3′ , 496 bp amplified
product. GAPDH was used as housekeeping gene to
control for loading.
Statistics
The ANOVA one-way test was used to determine statisti-
cal significance. A P value of less than 0.05 was considered
to be statistically significant.
Table 1. Cell cycle analysis
+VPA +TSA
control 1 mM/ 1 week 100 ng/ml 1 week
A375
% G1 76 64 –
% apoptosis 20 73 96
SK-Mel28
% G1 32 30 42
% apoptosis 8 8 45
Subconfluent cells (106) untreated or treated with VPA or TSA,
were trypsinized, fixed in ethanol and stained with PI (50 mg/ml)
as described in the Materials and Method section. DNA decon-
volutions have been carried out using the software program CEL-
LQUEST (Beclon-Dickinson).
The Tables shows the percentage of cells in G1 or in pre-G1
(apoptotic).
Results
Effect of VPA on the proliferation of four human
melanoma cell lines
We have compared the effect of three HDAC inhibitors
(VPA, SAHA and TSA) on four human melanoma cell
lines, that is, WM115 ( derived from primary melanoma),
WM266 (from metastatic melanoma), A375 (an amelan-
otyc cell line) and SK-Mel28 (a melanotyic cell line from
metastatic melanoma). In two out of four cell lines, VPA
inhibited the proliferation (65 and 33% for WM266 and
A375, respectively), while SK-Mel28 and WM115 hu-
man melanoma cells were resistant to VPA treatment
(Figure 1). Cytofluorimentric analyses supported that the
inhibition of proliferation was associated with induction
of apoptosis, as shown by appearance of cells with subG1
DNA content after drug exposure (Table 1). Since a short-
term incubation with VPA was less efficient (data not
shown), in all the experiments the cells were exposed to
1 mM VPA for a week. In contrast, TSA (72 h, 0.1 µg/ml)
or SAHA (4 or 8 µM, 72 h) treatments inhibited all the
analysed cell lines, leading to apoptosis (Figure 1 and
Table 1).
Analysis of hystone H3 and H4 acetylation
To examine the interference of the studied HDAC in-
hibitors with their target, we performed Western blot
analysis of the acetylation status of H3 and H4 histones.
Since in all the four human melanoma cell lines we ob-
tained similar results, in Figure 2 a typical experiment.
The status of acetylation of hystone H3 and H4 increased
after the treatment with VPA (1 mM) as well as after
TSA (100 ng/ml) or SAHA treatments (4 µM) (Figure 2,
Panel A and B). We, therefore, can exclude that the differ-
ential effects of VPA versus the other HDAC inhibitors in
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Figure 1. Cells were plated into 96-well plates (500, 1000, 4000 and 5000 cells/well for WM115, A375, SKMel28 and WM266, respec-
tively). 24 h later the cells were incubated with 100 ng/ml TSA, 4 µM SAHA or 8 µM SAHA for 72 h or with 1 mM VPA for a week. At
the end of the treatments the proliferative rate was evaluated using MTT-assay as described in the Materials and Methods section. The
results are expressed as percentage of cells with respect to untreated control cells. The values represent the means ± SE of at least
three independent experiments. ***, p < 0.001 vs. untreated cells.
Figure 2. Subconfluent cells treated with 5 ng/ml TSA or 1 µM SAHA for 72 h or with 1 mM VPA for a week were harvested by
tripsinization and collected by centrifugation. Cellular pellets were resuspended in sample buffer of Laemmli and boiled for 5 minutes. A
fixed number of cells (5 · 105 cells) for each treatment were submitted to 15% SDS-PAGE and blotted onto a PVDF sheet. The membrane
was incubated with anti-H3 (1:1000, UpState) or H4 (1:1000, UpState) antibody for 1 h at room temperature or with anti-non acetylated
antibody recognised both hystones overnight at 4◦C (1:1000, UpState). Immunocomplexes were visualized using ECL-Plus system
(Amersham).
different cell lines can be ascribed to the lack of efficient
induction of acetylation.
Bcl-2, BclXL/S, Mcl-1, NOXA, survivin and Apaf-1
expression
As VPA did not affect the proliferative capacity of SK-Mel
28 and WM115 melanoma cells, the differences in pro-
and anti-apoptotic factors between VPA-sensitive and -
resistant cells were investigated. We focused on Bcl-2,
Bcl-XL, Mcl-1 and survivin as anti-apoptotic genes and
Apaf-1 and Bcl-Xs and NOXA as pro-apoptotic ones.
Since SAHA and TSA produced the same effects, only
the results obtained with SAHA were presented. For the
same reason, only data from one of each VPA-sensitive
and -resistant cells, i.e., SK-Mel28 and WM266, were
shown below. Using RT-PCR we found that Bcl-2 was not
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Figure 3. Cell lysates were prepared from cells treated with 4 µM SAHA for 72 h or with 1 mM VPA for a week. Proteins (80 µg/sample)
were submitted to 15% SDS-PAGE and blotted onto a PVDF sheet. The membrane was incubated with antibodies directed against Bcl-2
(1:100, Dako), BclXS/L (1:2000, Pharmingen International) or anti-Apaf-1 (1:1000, Sigma) overnight at 4◦C. Immunocomplexes were
visualized using ECL-Plus system (Amersham). In order to check the correct loading, the same sheet was stripped and incubated with
anti-β-actin antibody (1:1000, 1 h), (data not shown).
expressed in VPA-resistant melanoma cell lines (Figure 3),
while these cells expressed BclXL, Mcl-1, BclXS at low
level and Apaf-1 (Figure 3). After VPA treatment, we
collected the adherent (surviving) cells using trypsin and
the expression of anti-apoptotic or pro-apoptotic factors
were analysed by Western blotting. The treatment with
VPA did not change either the level of expression of Bcl-2
or the level of expression of BclXL/S and Apaf-1 (Figure 3).
In contrast, in SAHA treated cells a decrease of both BclXS
and BclXL occurred (Figure 3). Furthermore, SAHA or
TSA treatments did not change the basal levels of Apaf-1
(data not shown).
Since both VPA-sensitive cell lines, WM266 and
A375, gave the same results, herein, the data of one of
the two cell line indifferently are shown. These cells ex-
pressed Bcl-2, at high level BclXS and Apaf-1 (Figure 3).
VPA-sensitive cells WM266 expressed Bcl-2, Apaf-1
and relatively high level of Bcl-XS (Figure 3). The
treatment with VPA, SAHA or TSA did not change
such a basal level except for Bcl-XL/S expression which
was decreased by SAHA treatment (Figure 3). In con-
trast, SAHA treatment did not change Bcl-2 levels
(Figure 3).
Finally, the pro-apoptotic gene NOXA, as well as the
anti-apoptotic gene survivin, and Mcl-1 were also de-
tected in untreated and treated cells (VPA or SAHA) by
RT-PCR (Figure 4). All untreated cells express NOXA
and survivin (Figure 4). VPA and SAHA treatments did
not modify the basal level of NOXA (Figure 4). Ei-
ther VPA or SAHA treatments significantly reduced the
level of expression of survivin only in VPA-sensitive cells
(Figure 4), while, in VPA-resistant cells, an increased level
of survivin occurred after VPA treatment (Figure 4). In
contrast, Mcl-1, another antiapoptotic factor, was not sig-
nificantly modulated by HDAC inhibitors (Figure 4).
Levels of TRAIL-R1 and -R2 in VPA-sensitive or
-resistant human melanoma cell lines
Binding of TRAIL to specific receptors (R1 and R2)
leads to the recruitment of FAS-associated death domain
(FADD), an adaptor molecule that recruits and activates
caspase-8. This initiates the caspase cascade that eventu-
ally leads to apoptosis through the activation of effector
caspases. Figure 5 shows one out of three independent
experiments carried out, all giving similar results. VPA
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Figure 4. Total RNA was purified from subconfluent untreated cells or VPA (7 days) or SAHA (72 h) treated ones using the RNeasy
Mini Kit from Qiagen. One microgram of total RNA were reverse transcribed and amplified by means of an “Enhanced avian hs RT-PCR”
(Sigma) according to the manufacturer’s instructions. PCR conditions and primers for NOXA, survivin and Mcl-1 are reported in the
Materials and Methods section. As housekeeping gene, GAPDH was used. Densitometric analysis was carried out using ImageMaster
software (Pharmacia Biotech).
induced an increase of TRAIL-R1 and -R2 expression only
in VPA-sensitive cells (Figure 5). Similar results were ob-
tained for SAHA from both VPA-sensitive and -resistant
cells (only data from VPA-sensitive cells were shown in
Figure 5). In contrast, none of the commercially available
antibodies work well in western blot, thereby we could
not detect the protein level of TRAIL-Rs.
Caspase 8 activation and HDACs treatment
The effect of HDAC inhibitors on caspase 8 activation
is shown in Figure 6. As positive control, Jurkatt cells
were treated with anti-Fas antibody concentration which
activates caspase 8 and leads to massive apoptosis (90%
of apoptotic cells). Caspase 8 is produced as a proen-
zyme which, upon receptor aggregation, is proteolyti-
cally cleaved into smaller subunits of 40/36(doublets)
and 23 kDa subunits.22 These subunits form a proteolyt-
ically active heterodimer capable of cleaving other cas-
pase family members as well as substrates such as PARP.
Herein we used an antibody which recognises both the
proform of caspase 8 (55/50 kDa doublets) as well as
the cleaved forms which migrate at 40/36 kDa (doublet)
and 23 kDa in SDS-Page.23,24 As shown in Figure 6, the
treatment with VPA activated caspase 8 only in VPA-
sensitive cells. In fact, the proteolytically cleaved forms
of caspase 8 (40/36 kDa and 23 kDa) appeared after the
treatment.
Discussion
Various melanomas show differences in their aggres-
sive biological behaviour and they also show di-
verse sensitivity to apoptotic stimuli, e.g. to TRAIL-
mediated apoptosis,15,25 γ -irradiation or chemo- and
immunotherapeutics.26
VPA is a well-tolerated drug even during long-term
treatment and, recently, it is proposed as a useful drug in
cancer therapy.10 VPA is known to cause hyper-acetylation
of the N-terminal tail of class I HDACs more efficiently
than class II enzymes in vitro and in vivo.10
In the present paper we studied the effect of different
HDAC inhibitors (VPA, TSA and SAHA) in four hu-
man melanoma cell lines. We show, for the first time,
that VPA differently from SAHA and TSA, acts only on
distinct cell lines, producing a peculiar pattern of modu-
lation of apoptotic factors. In fact, two out of four human
melanoma cell lines were sensitive to VPA (WM266 and
A375 cell lines were sensitive to VPA, while WM115 and
SK-Mel28 cells were resistant). In contrast, TSA or SAHA
treatments inhibited the proliferation in all the cell lines.
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Figure 5. Total RNA was purified form subconfluent untreated cells or VPA (2, 4, 7 days) (panel A) or SAHA (72 h) (Panel B) treated ones
using the RNeasy Mini Kit from Qiagen. One microgram oftotal RNA was reverse transcribed and amplified by means of an“Enhanced
avian hs RT-PCR” (Sigma) according to the manufacturer’s instructions. PCR conditions and primers for TRAIL-R1 and TRAIL-R2 are
reported in the Materials and Methods section. Jurkat cells expressing constitutively TRAIL-R1 and -R2 are used as positive control.
As housekeeping gene, GAPDH was used. Densitometric analysis was carried out using ImageMaster software (Pharmacia Biotech).
Panel A. Time course of expression of TRAIL-R1 and -R2 in VPA sensitive WM266 cells and in VPA resistant SK-Mel28 cells. Panel B.
Densitometric analysis of panel A.
Recently, similar results were obtained in leukemia cells
treated with VPA.27 However, since the analysis of the
status of acetylation of hystone H3 and H4 support the
inhibitory effect of VPA, we can exclude that the different
behaviour of VPA, SAHA or TSA in terms of antiprolifera-
tive/apoptotic effect can be ascribed to the lack of efficient
induction of HDACs.
Therefore, in order to elucidate the molecular mecha-
nisms triggered by VPA or other HDACs inhibitors such
as SAHA, we studied anti- and pro-apoptotic factors such
as Bcl-2, BclXL, Apaf-1, BclXs, NOXA, TRAIL-R1 and
-R2, Mcl-1 and survivin. Mcl-1 was included in our anal-
ysis as it is homolog to Bcl-2 and deeply involved in the
regulation of apoptosis in hemopoietic cells.28 In addi-
tion, Mcl-1 is downregulated in hemopoietic cells by ac-
tivation of the cAMP pathways in relation to cell viability
and differentiation.29,30 Finally, to better characterize the
apoptotic pathway possibly modulated by treatments (i.e
receptor-mediated apoptotic pathway) we also examined
the possible activation by HDACs inhibitors of caspase 8.
Firstly, our data demonstrate the baseline differences
in pro- and anti-apoptotic factors in VPA-sensitive and
-resistant cell lines. VPA-sensitive cells express as anti-
apoptotic factors Bcl-2, Mcl-1 and survivin and as pro-
apoptotic factors Apaf-1, BclXS and NOXA (Table 2). In
contrast, the resistant cell lines express as anti-apoptotic
factors, Mcl-1, BclXL and survivin and as pro-apoptotic
factors, NOXA and BclXS and Apaf-1. In the latter no
expression of Bcl-2 occurred (Table 2). Bcl-2 expression
is commonly found in melanocytes lesions, regardless of
their biological behaviour, but the progression of malig-
nant melanoma was shown to be independent of high
expression of Bcl2.31,32 Moreover, TRAIL-R1, -R2 and
Apaf-1 are expressed in all the human melanoma cell
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Figure 6. Cell lysates were prepared from cells treated with 4µM SAHA for 72 h or with 1 mM VPA for 4 or 7 days. Proteins (80
µg/sample) were submitted to 13% SDS-PAGE and blotted onto a PVDF sheet. The membrane was incubated with anti-caspase 8
(1:2000) overnight at 4◦C. Immunocomplexes were visualized using ECL-Plus system (Amersham). As positive control subconfluent
Jurkat cells are treated with anti-Fas antibody for 24 h (1 µg/ml) and then 80 µg of proteins are loaded on 13% SDS-PAGE gel. Arrows
show the procaspase 8 form of 55/50 kDa and the proteolytically forms of 45/40 kDa and 23 kDa.
lines analysed, irrespectively of sensitivity or resistance
to VPA. Interestingly, in human melanoma cells Mcl-1
is of functional relevance for survival and subject to dual
regulation by the MAP-kinase pathway and a pathway in-
volving protein kinase B/Akt.33 Secondly, VPA or SAHA
treatments modulate distinct pro- and anti-apoptotic fac-
tors (Table 3). In particular, VPA enhances the level of
survivin only in VPA- resistant cells. In the same cells
SAHA does not modify survivin levels, but decreased an-
other anti-apoptotic factor, BclXL, leading possibly the
balance versus apoptosis. In contrast, in VPA-sensitive
cells, both treatments (VPA or SAHA) decrease the level
of survivin. Thereby, the modulation of anti-apoptotic
factors such as survivin/BclXL seems to be important for
the induction of VPA apoptosis. Recently, an analogue of
polyamine was demonstrated to cause rapid apoptosis in
human melanoma SK-Mel28 cells degrading survivin.34
Accordingly, the attenuation of survivin expression was
demonstrated to make human melanomas more suscep-
Table 2. Effect of VPA on VPA-sensible and -resistant human melanoma cell lines. ↓,
decrease; -unchanged; ↑ increase
tible to gamma-irradiation.35 Down-regulation of sur-
vivin was also observed in acute leukaemia cells exposed
to the HDAC inhibitor LAQ824.36 More recently, the
expression of apoptosis-related genes has been evaluated
in sentinel lymph nodes from melanoma patients and
then correlated to the outcome of patients.37 This pa-
per demonstrated that survivin expression correlates with
the outcome patients and therefore it was a useful prog-
nostic indicator.37 On the other hand, the expression of
a phosphorylation-defective survivin mutant triggered
apoptosis in several human melanoma cell lines enhancing
cell death by antitumor drugs such as cisplatin.38 Regard-
ing to Mcl-1, our findings clearly show that VPA does not
modify its expression.
Thereby, survivin appears to be the main anti-apoptotic
factor modulated by HDAC inhibitors and our data
show for the first time that VPA acts on distinct hu-
man melanoma cells differently from other HDACs in-
hibitors. In fact, in addition to hyperacetylation, VPA was
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Table 3. Effect of SAHA on VPA sensible and resistant human melanoma cell lines. ↓,
decrease -unchanged; ↑ increase
reported to increase DNA binding of AP1 transcription
factor, to down-regulate protein kinase C (PKC) activity,
to inhibit glycogen synthase kinase -3 (GSK-3b), and it
also was reported to act as negative regulator of wnt sig-
nalling pathways.14 Therefore, it is tempting to speculate
that different intracellular pathways modulated by VPA
in distinct melanoma cells, could modify the expression
of survivin.
On the other hand, an interesting finding of this study
was that VPA affects mRNA levels of TRAIL-R1 and -
R2 expression differently in VPA-sensitive or -resistant
cells. In fact, VPA treatment induced an increase in both
receptors and activation of caspase 8 in VPA-sensitive
cells, which, however, was not observed in the resis-
tant cells. This observation suggests that the receptor-
mediated apoptotic pathway may also be involved in VPA
triggered apoptosis. These results which are in agreement
with recent observations in acute leukaemia cells36 sup-
port the potential interest of the combination of HDAC
inhibitors and TRAIL.
All of all, in view of a new therapeutic approach for
melanoma, our results show that a well tolerated drug
such as VPA can be effective in inducing cell death on a
subset of melanoma, (modulating in particular survivin
expression), and that the balance between pro- and anti-
apoptotic factors in distinct melanomas can account at
least in part for the responsiveness to distinct drugs.
Therefore, our findings suggest that HDAC inhibitors in-
cluding VPA, SAHA and TSA may represent a promising
therapeutic strategy to treat melanoma.
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